Home › Epithelial Carcinoma ng Ovary › Minnesota
Pag-aaral pangklinika para sa Epithelial Carcinoma ng Ovary sa Minnesota
7 pag-aaral para sa Epithelial Carcinoma ng Ovary ang naghahanap ng mga kalahok sa mga site sa Minnesota.
Mga Lungsod sa Minnesota
Opisyal na teksto ng pag-aaral (English)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Minnesota - Minneapolis /ID# 275718, Minneapolis
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Set 29, 2026 · NCT06890338Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Masonic Cancer Center, University of Minnesota, Minneapolis
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Set 15, 2026 · NCT06915025ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Mayo Clinic (Rochester), Rochester
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05059444AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Minneapolis
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Hul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Minnesota Oncology Hematology PA, Minneapolis
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Hul 2, 2026 · NCT06819007A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Mayo Clinic, Rochester
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT06395519CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Minnesota Oncology Hematology, P.A., Minneapolis
- University of Minnesota, Minneapolis
- Mayo Clinic, Rochester
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Dis 23, 2025 · NCT06690775Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.